Piotr J. Wysocki
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
Piotr J. Wysocki
Apr 12, 2024, 10:05 |
Drugs
Piotr J. Wysocki: Immunotherapy combined with tyrosine-kinase inhibitor is not better than docetaxel in NSCLS patients after first-line chemoimmunotherapy failure
Piotr J. Wysocki, Head of the Oncology Department at the University Hospital Krakow, shared a post…
Apr 12, 2024, 09:11 |
Opinion
Piotr J. Wysocki: PSA screening does reduce prostate cancer mortality, but the overall benefit is small, according to a secondary analysis of the CAP trial
Piotr J. Wysocki, Head of Department of Oncology at Jagiellonian University Hospital, shared a post…
Apr 5, 2024, 02:23 |
Insight
Piotr J. Wysocki: OPTICAL trial - another study demonstrating the feasibility and promising efficacy of neoadjuvant chemotherapy in locally advanced colon cancer
Piotr J. Wysocki, Head of the Oncology Department at the University Hospital Krakow, shared a post…
Apr 5, 2024, 01:51 |
Insight
Piotr J. Wysocki: Pembrolizumab significantly improves efficacy of chemoradiotherapy in patients with locally-advanced cervical cancer
Piotr J. Wysocki, Head of the Oncology Department at the University Hospital Krakow, shared a post…
Mar 30, 2024, 11:36 |
Insight
Piotr J. Wysocki: Pembrolizumab remains the only drug active in adjuvant settings in RCC – updated results of the ECOG-ACRIN E2810 on adjuvant pazopanib
Piotr J. Wysocki, Head of the Oncology Department at the University Hospital Krakow, shared a post…
Mar 22, 2024, 23:32 |
Insight
Piotr J. Wysocki: Ribociclib combined with an aromatase inhibitor in the adjuvant treatment of breast cancer – interim analysis of Natalee study
Piotr J. Wysocki, Head of the Oncology Department at the University Hospital Krakow, shared a post…
Mar 22, 2024, 15:23 |
Blog
Piotr J. Wysocki: Regular, personalized follow-up in breast cancer survivors may not improve long-term outcomes but significantly improves patients’ quality of life
Piotr J. Wysocki, Head of the Oncology Department at the University Hospital Krakow, shared a…
Mar 15, 2024, 15:26 |
Insight
Enfortumab+pembrolizumab combination as the 1st line treatment of choice for advanced urothelial cancer - summary by Piotr J. Wysocki
Piotr J. Wysocki, Professor of Medicine, Head of Department of Oncology at Jagiellonian University Hospital,…
Mar 5, 2024, 20:12 |
Insight
Piotr J. Wysocki: Final results of the POUT trial support the use of adjuvant chemotherapy in upper tract urothelial cancer
Piotr J. Wysocki, Professor of Medicine and Head of Department of Oncology at Jagiellonian University…
Mar 4, 2024, 17:27 |
Drugs
Piotr Wysocki: Anthracyclines must always be considered in the adjuvant treatment of breast cancer patients- final results of ABC trials
Piotr Wysocki, Professor of Medicine and Head of Department of Oncology at Jagiellonian University Hospital…
1
2
All:
15
Posts:
1 - 10
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Barbara Jereczek-Fossa has been elected as the ESTRO President-elect!
Neuroendocrine tumors - newly updated AJCC guidelines
5 min Sarcoma Talk with Shushan Hovsepyan and Andrea Ferrari
OncoInfluencers: Dialogue with Tony Mok, hosted by Gevorg Tamamyan
Facebook
RSS Feed
Twitter
Linkedin
Youtube